• PET radiopharmaceutical for Parkinson’s Disease

    - Signed with Columbia University for research for clinical research trial

    - Phase 1 trial in the works

  • PET radiopharmaceutical for Alzheimer’s Disease

    - Signed a license agreement with Moltek in Turkey

    - Preparation of product registration in process in Turkey

  • PET radiopharmaceutical for prostate cancer

    - Obtained US FDA IND approval for Phase 1 trial at the Johns Hopkins Hospital

    - Signed a license agreement with IASON GmbH in Europe

  • Therapeutic radiopharmaceutical for prostate cancer

    - Completed non-clinical trials

    - Signed a CRO agreement with Linical Korea

    - Phase 1 trial in progress

Chemical Business

For Japan NMP Business Support Co., Ltd. For Taiwan TAIWAN LIFE SUPPORT SYSTEMS, Inc. For USA Molecular Targeting Technologies, Inc. For USA IsoTherapeutics Group, LLC

Global Partners